Sennosides Tablet
Product Images NDC 62993-0001
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Sennosides (NDC 62993-0001). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Morepen Laboratories Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Primary Display Panel 1000 Tablets (1000 Tablets Pdp)
This is a description of Drug Facts for a medication containing Sennosides used as a laxative. The text provides directions for different age groups, including children, on dosages and frequency of use. It includes active and inactive ingredients, warnings about prolonged use, and possible side effects. The product is compared to active ingredients in Senokot and stored at a specific temperature range. Important information on when to stop using the product and when to seek medical help is also highlighted. Additionally, contact information for further inquiries or reporting of adverse effects is provided.*
Primary Display Panel 250 Tablets (250 Tablets Pdp)
Primary Display Panel 30 Tablets (30 Tablets Pdp)
This text appears to be a description of a product which offers gentle and dependable constipation relief, indicated for regular strength consumption. The product consists of 30 tablets containing Sennosides tablets. It is mentioned to contain Standardized Senna Concentrate of 8.6 mg. The product is compared to the active ingredient found in Senokot®.*
Primary Display Panel 3000 Tablets (3000 Tablets Pdp)
This is a drug facts sheet for Sennosides Tablets containing 8.6 mg of sennosides, a laxative used to relieve occasional constipation. The product provides gentle and dependable constipation relief, producing a bowel movement within 6-12 hours. The dosage instructions varying based on age range from adults to children under six years old. The tablets also contain inactive ingredients like calcium and precautions for usage are mentioned for pregnant or breastfeeding individuals. It is recommended to consult a healthcare professional before use, store at 25°C, and keep the product out of reach of children. For more information or questions, contact the manufacturer at the provided toll-free number or the FDA.*
Active Ingredient Label (Active Ingredient)
Dosage & Administration (Dosage And Administration)
Inactive Ingredients (Inactive Ingredient)
This text provides a list of inactive ingredients commonly found in medications. It includes croscarmellose sodium, dibasic calcium phosphate, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and polyethylene glycol. These ingredients are often used in the formulation of pharmaceutical products to help with binding, disintegration, and as fillers or lubricants.*
Keep Out Of Reach Of Children (Keep Out Of Reach Children)
Purpose (Purpose)
Questions (Questions)
This text provides contact information for inquiries or comments regarding a product or service. It includes a toll-free number (1-844-317-6549) for assistance during specific hours (Mon-Fri 9AM-5PM EST). Additionally, it suggests contacting the FDA at 1-800-FDA-1088 or visiting their website at www.fda.gov/medwatch for further information or reporting of any related issues.*
Storage And Handling (Storage And Handling)
Indications & Usage (Uses)
Warnings (Warnings Section)
This text contains warnings and instructions for the use of laxative products. It advises not to use laxatives for more than one week without doctor's direction and to stop use if experiencing certain symptoms like rectal bleeding or no bowel movement. It also recommends consulting a doctor before use if experiencing stomach pain, nausea, vomiting, or other digestive changes for a prolonged period. Additionally, it warns pregnant or breastfeeding individuals to seek guidance from a healthcare professional before use and stresses keeping the product out of children's reach. In case of overdose, immediate medical assistance is recommended.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.